sauvagine and Dilatation--Pathologic

sauvagine has been researched along with Dilatation--Pathologic* in 1 studies

Other Studies

1 other study(ies) available for sauvagine and Dilatation--Pathologic

ArticleYear
Peripheral injection of sauvagine prevents repeated colorectal distension-induced visceral pain in female rats.
    Peptides, 2005, Volume: 26, Issue:7

    We investigated the effects of peripheral injection of sauvagine, a CRF2>CRF1 receptor (corticotropin-releasing factor) agonist compared with CRF, on two sets of tonic colorectal distension (CRDs 30, 40, 50 mmHg, 3-min on/off)-induced visceromotor response (VMR) measured as area under the curve (AUC) of abdominal muscle contraction in conscious female rats. Sauvagine (10 or 20 microg/kg, s.c.) abolished the 226.7+/-64.3% and 90.4+/-38.1% increase in AUC to the 2nd CRD compared with the 1st CRD (performed 30 min before) in female Fisher and Sprague-Dawley (SD) rats, respectively. CRF had no effect while the CRF1 antagonist, antalarmin (20 mg/kg, s.c.), alone or with sauvagine, blocked the enhanced response to the 2nd CRD, performed 60 min after the 1st CRD, and reduced further the AUC by 33.5+/-23.3% and 63.5+/-7.2%, respectively in Fisher rats. These data suggest that peripheral CRF2 receptor activation exerts antinociceptive effects on CRD-induced visceral pain, whereas CRF1 contributes to visceral sensitization.

    Topics: Abdominal Pain; Amphibian Proteins; Animals; Colon; Dilatation, Pathologic; Female; Injections, Subcutaneous; Muscle Contraction; Peptide Hormones; Peptides; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Rectum

2005